In the earlier article covering the first argument, readers asked me why I thought a cross-species translation may be easier to consider than an intra-species translation like from those with mild to moderate hypertriglyceridemia to those with severe TGL. And the answer is provided in the brief, as follows: "This difference in patient populations is critical, because, as the record evidence made clear, skilled artisans understood patients with severe hypertriglyceridemia responded differently to triglyceride-lowering drugs because of their genetics than those with milder hypertriglyceridemia." So there was no way results from a trial in the